Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP9X | Q93008 | 10/20 | 0.50 |
| ▸ | USP24 | Q9UPU5 | 1/20 | 0.50 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.47 |
| ▸ | USP5 | P45974 | 1/20 | 0.47 |
| ▸ | GPR88 | Q9GZN0 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | ACACB | O00763 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL882286 | 0.94 | USP9X (0.48) | USP9XUSP24UCHL1USP5GPR88 | |
| SCHEMBL882575 | 0.83 | USP9X (0.64) | USP9XUSP24UCHL1USP5ALDH1A1 | |
| SCHEMBL20171590 | 0.83 | USP9X (0.40) | USP9XUSP24UCHL1USP5GPR88 | |
| SCHEMBL10124876 | 0.83 | USP9X (0.54) | USP9XUSP24UCHL1USP5GPR88 | |
| SCHEMBL10124920 | 0.82 | USP9X (0.58) | USP9XUSP24UCHL1USP5GPR88 | |
| SCHEMBL10125141 | 0.79 | USP9X (0.56) | USP9XUSP24UCHL1USP5GPR88 | |
| SCHEMBL882277 | 0.78 | USP9X (0.52) | USP9XUSP24UCHL1USP5GPR88 | |
| SCHEMBL16273263 | 0.77 | USP9X (0.52) | USP9XUSP24UCHL1USP5GPR88 | |
| SCHEMBL10124855 | 0.77 | USP9X (0.56) | USP9XUSP24UCHL1USP5GPR88 | |
| SCHEMBL882298 | 0.76 | USP9X (0.55) | USP9XUSP24UCHL1USP5GPR88 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140357673-A1 | Deubiquitinase Inhibitors and Methods for Use of the Same | UNIV MICHIGAN (US) | 2014-12-04 | — | — | US | disclosed |
| US-8809377-B2 | Deubiquitinase inhibitors and methods for use of the same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-08-19 | — | — | US | disclosed |
| US-20120077806-A1 | Deubiquitinase Inhibitors and Methods for Use of the Same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140357673-A1 | Deubiquitinase Inhibitors and Methods for Use of the Same | UCHL1, USP2, USP1 | USP9X 33/4885USP24 28/4885UCHL1 1/4885 |
| US-20120077806-A1 | Deubiquitinase Inhibitors and Methods for Use of the Same | UCHL1, USP2, USP1 | USP9X 33/4885USP24 28/4885UCHL1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.